

**Please cite the Published Version**

Hampden-Martin, Alistair, Fothergill, Jo, El Mohtadi, Mohamed, Chambers, Lucy, Slate, Anthony J, Whitehead, Kathryn A and Shokrollahi, Kayvan (2021) Photodynamic antimicrobial chemotherapy coupled with the use of the photosensitizers methylene blue and temoporfin as a potential novel treatment for *Staphylococcus aureus* in burn infections. *Access Microbiology*, 3 (10). 000273-000273.

**DOI:** <https://doi.org/10.1099/acmi.0.000273>

**Publisher:** Microbiology Society

**Version:** Published Version

**Downloaded from:** <https://e-space.mmu.ac.uk/630973/>

**Usage rights:**  [Creative Commons: Attribution-Noncommercial 4.0](https://creativecommons.org/licenses/by-nc/4.0/)

**Additional Information:** This is an Open Access article published in *Access Microbiology* by Microbiology Society.

**Enquiries:**

If you have questions about this document, contact [openresearch@mmu.ac.uk](mailto:openresearch@mmu.ac.uk). Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

# Photodynamic antimicrobial chemotherapy coupled with the use of the photosensitizers methylene blue and temoporfin as a potential novel treatment for *Staphylococcus aureus* in burn infections

Alistair Hampden-Martin<sup>1</sup>, Jo Fothergill<sup>2</sup>, Mohamed El Mohtadi<sup>3</sup>, Lucy Chambers<sup>4</sup>, Anthony J. Slate<sup>5</sup>, Kathryn A. Whitehead<sup>4,\*</sup> and Kayvan Shokrollahi<sup>6,\*</sup>

## Abstract

Photodynamic antimicrobial chemotherapy (PACT) is a novel alternative antimicrobial therapy that elicits a broad mechanism of action and therefore has a low probability of generating resistance. Such properties make PACT ideally suited for utilization in localized applications such as burn wounds. The aim of this study was to determine the antimicrobial activity of MB and temoporfin against both a *S. aureus* isolate and a *P. aeruginosa* isolate in light (640 nm) and dark conditions at a range of time points (0–20 min). A *Staphylococcus aureus* isolate and a *Pseudomonas aeruginosa* isolate were treated *in vitro* with methylene blue (MB) and temoporfin under different conditions following exposure to light at 640 nm and in no-light (dark) conditions. Bacterial cell viability [colony-forming units (c.f.u.) ml<sup>-1</sup>] was then calculated. Against *P. aeruginosa*, when MB was used as the photosensitizer, no phototoxic effect was observed in either light or dark conditions. After treatment with temoporfin, a reduction of less than one log (7.00×10<sup>7</sup> c.f.u. ml<sup>-1</sup>) was observed in the light after 20 min of exposure. However, temoporfin completely eradicated *S. aureus* in both light and dark conditions after 1 min (where a seven log reduction in c.f.u. ml<sup>-1</sup> was observed). Methylene blue resulted in a loss of *S. aureus* viability, with a two log reduction in bacterial viability (c.f.u. ml<sup>-1</sup>) reported in both light and dark conditions after 20 min exposure time. Temoporfin demonstrated greater antimicrobial efficacy than MB against both the *S. aureus* and *P. aeruginosa* isolates tested. At 12.5 μM temoporfin resulted in complete eradication of *S. aureus*. In light of this study, further research into the validity of PACT, coupled with the photosensitizers (such as temoporfin), should be conducted in order to potentially develop alternative antimicrobial treatment regimes for burn wounds.

## INTRODUCTION

Widespread antibiotic misuse, coupled with an increasingly mobile global population, has facilitated an alarming increase in the rates of emerging antimicrobial-resistant (AMR) bacteria. The treatment of AMR bacteria results in both a decline in the physiological and psychological well-being of patients (including morbidity and mortality) and serious financial burdens to healthcare providers and their respective countries worldwide [1]. In Europe alone, multidrug-resistant

(MDR) bacteria are estimated to be responsible for ~25000 deaths per year [2]. Furthermore, it is estimated that by 2050 mortality rates attributed to AMR bacterial infections will surpass 10 million people per annum, superseding cancer as the leading cause of global mortality [3, 4]. Commonly isolated AMR bacteria from patients include methicillin-resistant *Staphylococcus aureus* (MRSA) [5], vancomycin-resistant *Enterococcus* spp. (VRE) [6], carbapenem-resistant *Enterobacteriaceae* spp. [7] and MDR *Pseudomonas* spp. [8].

Received 13 May 2021; Accepted 11 August 2021; Published 27 October 2021

**Author affiliations:** <sup>1</sup>Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; <sup>2</sup>Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; <sup>3</sup>Department of Biology, Edge Hill University, Ormskirk, Lancashire, L39 4QP, UK; <sup>4</sup>Microbiology at Interfaces, Manchester Metropolitan University, Manchester, UK; <sup>5</sup>Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK; <sup>6</sup>Mersey Regional Burns and Plastic Surgery Unit, Whiston Hospital, Liverpool, UK.

**\*Correspondence:** Kayvan Shokrollahi, Kayvan.Shokrollahi@sthk.nhs.uk; Kathryn A. Whitehead, k.a.whitehead@mmu.ac.uk

**Keywords:** bacteria; burns; infection; methylene blue; photodynamic antimicrobial chemotherapy; temoporfin.

**Abbreviations:** AMR, antimicrobial resistant; ANOVA, two-way analysis of variance; c.f.u. ml<sup>-1</sup>, colony forming units per milliliter; EPI-MB, efflux pump inhibitor-methylene blue; LB, Luria-Bertani broth; LED, light-emitting diode; L+P-, with light but with no photosensitizer; L-P-, without the light and a photosensitizer; L-P+, with no light but with a photosensitizer; MB, methylene blue; MDR, multidrug resistant; PACT, photodynamic antimicrobial chemotherapy; PDT, photodynamic therapy; TB, toluidine blue; VRE, vancomycin-resistant *Enterococcus* spp.

000273 © 2021 The Authors



This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author's institution.

The main therapeutic strategies that are currently used to control AMR include antimicrobial stewardship, improved infection control and the development of new antimicrobials (including novel antibiotics) [9]. However, since the 'golden era' of antibiotic discovery (~1950–1970) [10], the development and approval of novel antibiotic classes has decreased significantly. This is mainly due to the high cost (>USD \$1 billion for new molecular entities) involved in antibiotic development, the low success rate and a lengthy process time (10–15 years) [11, 12]. In addition, the limited mechanism of action of most antibiotics has indicated that resistance is likely to develop and therefore novel antibiotics potentially have a limited shelf life [9].

Burns patients are at high risk of nosocomial infection due to compromised innate host defences (in this instance damage to the epidermis) [13]. Bacterial colonization of burns can result in invasive infection, septicaemia, multi-organ failure and ultimately death [14]. *Pseudomonas aeruginosa* is the most commonly isolated bacteria from burn wounds, followed by *S. aureus* [15].

The antimicrobial effect of photodynamic antimicrobial chemotherapy (PACT) relies on three components: the presence of oxygen (O<sub>2</sub>), a photosensitizer and a wavelength of light that coincides with the peak absorption of the photosensitizers [16]. Methylene blue (MB) is a well-established photosensitizer that has been extensively documented throughout the past decade [17, 18]. Due to the antimicrobial efficacy of MB against a broad range of micro-organisms it is often utilized as a potent photodynamic therapy (PDT) drug for the local treatment of periodontal diseases [19, 20]. The efficiency of MB-mediated PACT has also been confirmed on antibiotic-resistant polymicrobial biofilms of *P. aeruginosa* and MRSA in a maxillary sinus model [21]. In addition, several *in vitro* studies have assessed its antimicrobial efficacy against a range of bacteria commonly isolated from burn infections [22, 23].

Temoporfin is a second-generation photosensitizer that has been utilized successfully in PDT to treat squamous cell carcinoma of the head and neck and has been investigated for use as a treatment for other cancers, such as biliary tract carcinomas [24, 25]. Temoporfin has been shown to achieve the same PDT response at lower concentrations and with lower light doses than its first-generation predecessors [26, 27]. In addition, temoporfin has a better safety profile than other photosensitizers, as it does not cause damage to underlying anatomical structures [26, 27]. Therefore, temoporfin has potential as a promising photosensitizer, although its antibacterial efficacy has not yet been thoroughly characterized in the context of burn infections.

Novel therapies to treat burn infections are urgently needed; particularly therapies that will not facilitate the development of antimicrobial resistance. One potential avenue to be explored is PACT. The current study aimed to assess the antimicrobial efficacy of methylene blue- and temoporfin-mediated PACT against both Gram-positive and Gram-negative bacterial species (namely *S. aureus* and *P. aeruginosa*) that are commonly isolated from burn infections

## METHODS

### Bacterial cultures


*S. aureus* (NCTC 6571) and *P. aeruginosa* (B9T2436) were utilized throughout this study. Both species of bacteria were cultured aerobically in Luria–Bertani broth (LB) (Fisher Scientific, USA) in a shaking incubator at 180 r.p.m. for 24 h at 37°C. Following incubation, the bacterial cultures were normalized in LB broth to achieve an optical density (OD<sub>600 nm</sub>) of 0.05 (±0.01), equating to approximately 1.0×10<sup>6</sup> colony-forming units (c.f.u.) ml<sup>-1</sup>.

### Photosensitizers and light source

Methylene blue (Sigma Aldrich, UK) was dissolved in sterile water to produce a 1% stock solution (w/v) (10 mg ml<sup>-1</sup>). Temoporfin (Sigma Aldrich, UK) was dissolved in absolute ethanol (≥99.8%; Sigma Aldrich, UK) at a concentration of 1 mM and stored at –20°C prior to use. Both photosensitizers were stored in a dark environment to minimize light exposure prior to experimentation. For the MB PACT experiments, the concentration of MB used was 1 mg ml<sup>-1</sup> (3.13 mM) and the concentration of temoporfin was 50 μM for *P. aeruginosa* and 12.5 μM for *S. aureus*. A portable light-emitting diode (LED) PDT light source that had a red wavelength (λ) (640 nm) was utilized throughout this study. Previous studies have determined that the maximum absorption for methylene blue and temoporfin is 668 and 650 nm, respectively [27, 28].

### PACT assays

Photodynamic antimicrobial chemotherapy experiments were conducted in clear, flat-bottom, 96-well microtitration plates (Fisher Scientific, UK). *S. aureus* and *P. aeruginosa* were exposed to four different parameters in the presence of both MB and temoporfin, and red light. A maximal light exposure time of 20 min was used, due to the assumption that patients would tolerate longer treatment times poorly. All PACT experiments were conducted in triplicate alongside a LB broth (negative control) (n=3). The bacteria were tested in the presence of the light and a photosensitizer (L+P+) – methylene blue (1 mg ml<sup>-1</sup>) or temoporfin (50 μM used for *P. aeruginosa* and 12.5 μM for *S. aureus*). The bacterial suspensions (~1.0×10<sup>6</sup> c.f.u. ml<sup>-1</sup>) were incubated in the dark for 20 min by covering the sterile microtitre plates with aluminium foil. Samples were illuminated using red light (λ=640 nm) for up to 20 min. Serial dilutions were performed at intervals of 1, 10 and 20 min of light exposure and plated onto LB agar plates (Fisher Scientific, USA). The inoculated agar was incubated overnight at 37°C in the dark. After incubation, the bacterial colonies were enumerated and the c.f.u. ml<sup>-1</sup> determined. The antimicrobial efficacy testing for the light and the photosensitizer was also carried out without the light and a photosensitizer (L–P–) as a negative control, with no light but with a photosensitizer (L–P+) or with light but with no photosensitizer (L+P–).



**Fig. 1.** Effect of MB (1 mg ml<sup>-1</sup>) on *P. aeruginosa* (B9T2436) after 1, 10 and 20 min of red light exposure ( $\lambda=640$  nm;  $n=3$ ). Group L+P+, incubated with MB for 20 min, and then irradiated with red light. Group L+P-, no incubation with MB but exposed to red light. Group L-P-, no incubation with MB or exposure to red light. Group L-P+, incubated with MB, but not exposed to red light. Bars represent median value +range of three biological replicates. Two-way ANOVA tests were performed between experimental groups at different time points. Asterisks denote significance (\* $P\leq 0.05$ , \*\* $P\leq 0.01$ ).

## Statistical analysis

Statistical analysis was conducted by performing two-way analysis of variance (ANOVA) coupled with Tukey's multiple comparison tests for post hoc analysis using GraphPad Prism (version 8.4.2; GraphPad Software, USA) to determine significant differences at a confidence level of 95% ( $P<0.05$ ). Error bars represent the standard error of the mean. Asterisks denote significance, \* $P\leq 0.05$ , \*\* $P\leq 0.01$ , \*\*\* $P\leq 0.001$  and \*\*\*\* $P\leq 0.0001$ .

## RESULTS

### The effect of MB- and temoporfin-mediated PDT on *P. aeruginosa*


Initially, the effect of PACT using MB on *P. aeruginosa* was determined. It was demonstrated that the number of viable cells increased with increased light exposure in the untreated experimental group (L-P-) with a mean of  $5.44\times 10^7$  c.f.u. ml<sup>-1</sup> at 1 min and  $8.00\times 10^7$  c.f.u. ml<sup>-1</sup> by 20 min (Fig. 1). There was also a similar pattern observed with the L+P+ and L+P- groups. The L-P+ group, representing the dark control and hence the antimicrobial activity of MB alone, was the only group to show a decrease in the number of viable cells with increasing time. However, no statistical difference was found between the negative control (L-P-) and (L-P+) at 20 min ( $P=0.9434$ ) (Fig. 1).

The effect of temoporfin-mediated PACT on *P. aeruginosa* was determined. In contrast to the MB-mediated PACT experiment with *P. aeruginosa*, the L+P+ group demonstrated a


decrease in cell viability from  $1.49\times 10^8$  c.f.u. ml<sup>-1</sup> at 1 min to  $7.00\times 10^7$  c.f.u. ml<sup>-1</sup> by 20 min. The number of bacterial colonies present at 20 min was significantly lower than for all other experimental groups. The bacterial viability (c.f.u. ml<sup>-1</sup>) in the L-P- group was  $2.89\times 10^8$  c.f.u. ml<sup>-1</sup> at 20 min, and the antimicrobial effect of temoporfin with 20 min of red light exposure resulted in  $7.00\times 10^7$  c.f.u. ml<sup>-1</sup> (Fig. 2).

### The effect of MB- and temoporfin-mediated PDT on *S. aureus*

The MB-mediated PACT experiments demonstrated that the Gram-positive bacterium, *S. aureus*, was more susceptible to MB than the Gram-negative bacterium, *P. aeruginosa*. Cell viability was determined at  $2.83\times 10^7$  c.f.u. ml<sup>-1</sup> and  $2.05\times 10^6$  c.f.u. ml<sup>-1</sup> between 1 and 20 min in the L-P+ and L+P+ groups, respectively (Fig. 3). The viable bacterial counts were higher (with statistical significance) in the experimental controls compared to the L+P+ and L-P+ groups at 1, 10 and 20 min, indicating that MB demonstrated antimicrobial efficacy under both light and dark conditions against *S. aureus*. The toxicity of MB alone when no light was applied had a greater effect on *S. aureus* than when illuminated, with the c.f.u. ml<sup>-1</sup> being consistently lower at 1, 10 and 20 min in the L-P+ group when compared to the L+P+ group. Relative to the control (L-P-) at 20 min ( $1.79\times 10^7$  c.f.u. ml<sup>-1</sup>), when MB was used without exposure to light (L-P+), a reduction in viable *S. aureus* ( $1.50\times 10^5$  c.f.u. ml<sup>-1</sup>) was achieved, whilst



**Fig. 2.** Effect of temoporfin (50  $\mu$ M) on *P. aeruginosa* (B9T2436) after 1, 10 and 20 min of red light exposure ( $\lambda=640$  nm;  $n=3$ ). Group L+P+, incubated with temoporfin for 20 min, and then exposed to red light. Group L+P-, not incubated with temoporfin but exposed to red light. Group L-P-, not incubated with temoporfin or exposed to red light. Group L-P+, incubated with temoporfin but not exposed to red light. Bars represent the mean of three biological replicates whilst error bars denote standard error of mean (SEM). Two-way ANOVA tests were performed between experimental groups at different time points. Asterisks denote significance (\* $P\leq 0.05$ ).



**Fig. 3.** Effect of MB (1 mg ml<sup>-1</sup>) on *S. aureus* c.f.u. ml<sup>-1</sup> after 1, 10 and 20 min of red light exposure ( $\lambda=640$  nm;  $n=3$ ). Group L+P+, incubated with MB for 20 min, and then exposed to red light. Group L+P-, no incubation with MB but exposed to red light. Group L-P-, no exposure to MB and no exposure to red light. Group L-P+, incubation with MB but no exposure to red light. Bars represent the mean of three biological replicates whilst error bars denote standard error of mean (SEM). Two-way ANOVA tests were performed between experimental groups at different time points. Asterisks denote significance (\* $P\leq 0.05$ , \*\* $P\leq 0.01$  and \*\*\* $P\leq 0.001$ ).

the phototoxicity group, L+P+, reported  $8.67\times 10^5$  c.f.u. ml<sup>-1</sup> of viable *S. aureus* (Fig. 3).


Temoporfin also demonstrated greater antimicrobial efficacy against the Gram-positive bacterium, *S. aureus* (Fig. 4). The killing effect of temoporfin at 12.5  $\mu$ M was substantially greater than that of MB (which was tested at a higher concentration of 3.13 mM), with a complete eradication of *S. aureus* observed in both the L-P+ and L+P+ groups after 1 min (Fig. 4). The L-P+ and L+P+ groups both showed statistically significant differences from the L-P- and L+P- groups at 1, 10 and 20 min. This indicated that temoporfin had an antimicrobial effect against *S. aureus* in the dark at 12.5  $\mu$ M, with complete eradication observed after 1 min of incubation (Fig. 4).

## DISCUSSION

This study aimed to determine the efficacy of light-activated photosensitizers against bacterial species commonly found in burn wound infections. The results from this *in vitro* study demonstrated that *S. aureus* (a Gram-positive bacterium) was more susceptible to killing by the photosensitizers in the absence of light than *P. aeruginosa* (a Gram-negative bacterium). Temoporfin demonstrated a photodynamic effect against *P. aeruginosa* and did not demonstrate an antimicrobial effect in the absence of light against *P. aeruginosa*. Incubation of *S. aureus* with temoporfin at 12.5  $\mu$ M (but no light exposure) demonstrated antimicrobial activity, with complete bacterial eradication after 1 min. Temoporfin at 12.5  $\mu$ M combined with red light exposure also resulted in the complete loss of *S. aureus* viability after

1 min, and therefore exclusive phototoxicity activity could not conclusively be determined. The toxicity of MB when tested against *S. aureus* in the dark was greater than its antimicrobial activity following exposure to light. MB did not demonstrate an antimicrobial effect in the absence of light against *P. aeruginosa*.

The greater sensitivity of Gram-positive bacteria to photosensitizers has been reported by other *in vitro* studies. In 2001, Usacheva *et al.* detailed the photobactericidal efficacy of the photosensitizers, MB and toluidine blue (TB), which was assessed against a range of Gram-positive and Gram-negative bacteria [20]. It was reported that the concentrations of both temoporfin and MB required to achieve complete eradication of Gram-negative bacteria with light were in general 3- to 30-fold higher than those required to kill the Gram-positive bacteria tested. Another *in vitro* study conducted by Yang *et al.* (2012) reported complete eradication of MRSA with temoporfin after a 90 min incubation period followed by continuous exposure to 100 J cm<sup>-2</sup> of light ( $\lambda=652$  nm) [29]. The discrepancy in sensitivity is believed to be due to differences in cell wall structure, with Gram-negative bacteria having an additional negatively charged outer membrane that impedes the diffusion of non-cationic photosensitizers [30]. However, this does not fully explain the decreased efficacy of MB, as it is a positively charged photosensitizer. An alternative explanation was provided in a study



**Fig. 4.** Effect of temoporfin (12.5  $\mu$ M) on *S. aureus* c.f.u. ml<sup>-1</sup> after 1, 10 and 20 min of red light exposure ( $\lambda=640$  nm;  $n=3$ ). Group L+P+, incubated with temoporfin for 20 min, and then exposed to red light. Group L+P-, no incubation with temoporfin but exposed to red light. Group L-P-, no incubation with temoporfin or exposure to red light. Group L-P+, incubated with temoporfin but not exposed to red light. Bars represent the mean of three biological replicates whilst error bars denote standard error of mean (SEM). Two-way ANOVA tests were performed between experimental groups at different time points. Asterisks denote significance (\* $P\leq 0.05$ , \*\* $P\leq 0.01$  and \*\*\* $P\leq 0.001$ ).

by Rineh *et al.* (2018), which reported a potential efflux mechanism against MB [31]. In this study it was shown that a NorA efflux pump inhibitor–methylene blue (EPI–MB) hybrid compound displayed a greater PDT against the Gram-negative bacteria *Escherichia coli* and *Acinetobacter baumannii* than MB alone. The antimicrobial activity against Gram-negative bacteria may therefore be enhanced by mitigating the effect of efflux pumps, through the use of shorter incubation times with photosensitizers, or by repeated doses of photosensitizers.

Another potential explanation for the poor photodynamic efficacy of MB against *P. aeruginosa* is a phenomenon called the self-shielding effect [30]. This arises when high concentrations of the photosensitizer are present in solution and absorb a significant proportion of the light, thereby reducing the light exposure to photosensitizer-loaded cells [30]. For many photosensitizers this self-shielding effect is observed when the concentration reaches  $\geq 300 \mu\text{M}$  [30]. The concentration of MB used throughout this study was 3.13 mM and was greater than that of the temoporfin, and was selected since studies in this area use a range of MB concentrations from  $\leq 25 \mu\text{g ml}^{-1}$  to  $10 \text{ mg ml}^{-1}$  and hence the MB concentration selected for use in this study was taken for use at a conservative mid-range [30, 32–34]. The use of this higher concentration may explain the potential shielding effect demonstrated.

The current study demonstrated that a temoporfin concentration of  $50 \mu\text{M}$  enabled a photodynamic effect to be observed against *P. aeruginosa*. *P. aeruginosa* cell viability at this concentration reduced from  $2.89 \times 10^8$  to  $7.00 \times 10^7$  c.f.u.  $\text{ml}^{-1}$ . In a previous study by Yang *et al.* (2012), a similar phenomenon was observed; no overall significant reduction in *P. aeruginosa* viability was observed when temoporfin was utilized at  $12.5 \mu\text{M}$ , and the authors stated that this was likely due to the neutral charge of temoporfin, which meant that penetration of the outer membrane was less probable [29]. The threshold required by the American Society of Microbiology for a treatment to be termed antimicrobial is when it can achieve at least a three log reduction in c.f.u.  $\text{ml}^{-1}$  (killing efficiency of 99.9%) [35]. It would therefore appear to be an ineffective antimicrobial treatment against antibiotic-resistant Gram-negative bacteria when used at this concentration.

Future research may involve the use of temoporfin as a photosensitizer against resistant strains of bacteria, in particular MRSA, as this species commonly colonizes burn wounds. This research has shown that temoporfin is effective in the eradication of a Gram-positive *S. aureus* species, meaning that it may result in the killing of other Gram-positive species causing burn infections, such as *Enterococcus* spp. This has been shown by Kranz *et al.* (2011), who described a six log reduction in *Enterococcus faecalis* c.f.u.  $\text{ml}^{-1}$  after treatment with  $30 \mu\text{M}$  of a liposomal formulation of temoporfin, subjected to a light dose of  $100 \text{ J cm}^{-2}$ , at a wavelength of  $652 \text{ nm}$  [36].

## CONCLUSIONS

Temoporfin demonstrated greater antimicrobial efficacy than MB against a *S. aureus* isolate and a *P. aeruginosa* isolate tested *in vitro*. At  $12.5 \mu\text{M}$ , temoporfin resulted in complete eradication of *S. aureus*. Although the use of light and temoporfin decreased the numbers of *P. aeruginosa*, viable cells were still present following treatment. The results of this study demonstrate that the antimicrobial activity of temoporfin as a photosensitizer could be more suited to Gram-positive bacterial infections. In light of this study, further research is warranted for the development of an alternative treatment option for burn wound infections.

### Funding information

This research received funding from the University of Liverpool.

### Author contributions

A.H-M. carried out the laboratory work and produced the initial draft of the work. J.F. and K.S. devised the concept and supervised the project. J.F., M.E.L.M., L.C., A.S. and K.W. were involved in analysis of the data. All the authors were involved in the preparation and proofreading of the manuscript. All authors approved the final version of this manuscript.

### Conflicts of interest

The authors declare that there are no conflicts of interest.

### References

1. Wainwright M, Maisch T, Nonell S, Plaetzer K, Almeida A, *et al.* Photoantimicrobials—are we afraid of the light? *Lancet Infect Dis* 2017;17:e49–e55.
2. European Commission. A European One Health Action Plan against Antimicrobial Resistance (AMR). 2017. [https://ec.europa.eu/health/amr/sites/amr/files/amr\\_action\\_plan\\_2017\\_en.pdf](https://ec.europa.eu/health/amr/sites/amr/files/amr_action_plan_2017_en.pdf)
3. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. 2016.
4. Butler JA, Slate AJ, Todd DB, Airtton D, Hardman M, *et al.* A traditional Ugandan *Ficus natalensis* bark cloth exhibits antimicrobial activity against Methicillin-Resistant *Staphylococcus aureus*. *J Appl Microbiol* 2020;131:2–10.
5. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, *et al.* Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. *Clin Infect Dis* 2001;32:S114–32.
6. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. *Infect Control Hosp Epidemiol* 2003;24:251–256.
7. Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, *et al.* Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. *Antimicrob Resist Infect Control* 2013;2:31.
8. Tangden T. Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. *Ups J Med Sci* 2014;119:149–153.
9. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. *N Engl J Med* 2013;368:299–302.
10. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. *Front Microbiol* 2010;1:134.
11. Kraus CN. Low hanging fruit in infectious disease drug development. *Curr Opin Microbiol* 2008;11:434–438.
12. Martens E, Demain AL. The antibiotic resistance crisis, with a focus on the United States. *J Antibiot* 2017;70:520–526.
13. Lachiewicz AM, Hauck CG, Weber DJ, Cairns BA, van Duin D. Bacterial infections after burn injuries: impact of multidrug resistance. *Clin Infect Dis* 2017;65:2130–2136.

14. Kalligeros M, Shehadeh F, Karageorgos SA, Zacharioudakis IM, Eleftherios E. MRSA colonization and acquisition in the burn unit: A systematic review and meta-analysis. *Burns* 2019;45:1528–1536.
15. Decraene V, Ghebrehewet S, Dardamissis E, Huyton R, Mortimer K, et al. An outbreak of multidrug-resistant *Pseudomonas aeruginosa* in a burns service in the north of England: Challenges of infection prevention and control in a complex setting. *J Hosp Infect* 2018;100:e239–e245.
16. Vatansever F, de Melo WC, Avci P, Vecchio D, Sadasivam M, et al. Antimicrobial strategies centered around reactive oxygen species-bactericidal antibiotics, photodynamic therapy, and beyond. *FEMS Microbiol Rev* 2013;37:955–989.
17. Hamblin MR. Antimicrobial photodynamic inactivation: a bright new technique to kill resistant microbes. *Curr Opin Microbiol* 2016;33:67–73.
18. Wainwright M, Crossley KB. Methylene Blue—a therapeutic dye for all seasons. *J Chemother* 2002;14:431–443.
19. de Souza SC, Junqueira JC, Balducci I, Koga-Ito CY, Munin E, et al. Photosensitization of different *Candida* species by low power laser light. *J Photochem Photobiol B* 2006;83:34–38.
20. Usacheva MN, Teichert MC, Biel MA. Comparison of the methylene blue and toluidine blue photobactericidal efficacy against Gram-positive and Gram-negative microorganisms. *Lasers Surg Med* 2001;29:165–173.
21. Kofler B, Romani A, Pritz C, Steinbichler TB, Scharfingger VH, et al. Photodynamic effect of methylene blue and low level laser radiation in head and neck squamous cell carcinoma cell lines. *Int J Mol Sci* 2018;19:E1107.
22. Wainwright M, Phoenix DA, Rice L, Burrow SM, Waring J. Increased cytotoxicity and phototoxicity in the methylene blue series via chromophore methylation. *J Photochem Photobiol B* 1997;40:233–239.
23. Ragàs X, Dai T, Tegós GP, Agut M, Nonell S, et al. Photodynamic inactivation of *Acinetobacter baumannii* using phenothiazinium dyes: In vitro and in vivo studies. *Lasers Surg Med* 2010;42:384–390.
24. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. *J Hematol Oncol* 2010;3:5.
25. Wagner A, Denzer UW, Neureiter D, Kiesslich T, Puespoeck A, et al. Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study. *Hepatology* 2015;62:1456–1465.
26. Berlanda J, Kiesslich T, Engelhardt V, Krammer B, Plaetzer K. Comparative *in vitro* study on the characteristics of different photosensitizers employed in PDT. *J Photochem Photobiol B* 2010;100:173–180.
27. Senge MO, Brandt JC. Temoporfin (Foscan(R), 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)—a second-generation photosensitizer. *Photochem Photobiol* 2011;87:1240–1296.
28. Whang TJ, Huang HY, Hsieh MT, Chen JJ. Laser-induced silver nanoparticles on titanium oxide for photocatalytic degradation of methylene blue. *Int J Mol Sci* 2009;10:4707–4718.
29. Yang K, Gitter B, Ruger R, Albrecht V, Wieland GD, et al. Wheat germ agglutinin modified liposomes for the photodynamic inactivation of bacteria. *Photochem Photobiol* 2012;88:548–556.
30. Huang L, Dai T, Hamblin MR. Antimicrobial photodynamic inactivation and photodynamic therapy for infections. *Methods Mol Biol* 2010;635:155–173.
31. Rineh A, Bremner JB, Hamblin MR, Ball AR, Tegós GP, et al. Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of *Escherichia coli* and *Acinetobacter baumannii* in vitro and in vivo. *Bioorg Med Chem Lett* 2018;28:2736–2740.
32. Wainwright M, Phoenix DA, Marland J, Wareing DRA, Bolton FJ. A study of photobactericidal activity in the phenothiazinium series. *FEMS Immunol Med Microbiol* 1997;19:75–80.
33. Gad F, Zahra T, Hasan T, Hamblin MR. Effects of growth phase and extracellular slime on photodynamic inactivation of Gram-positive pathogenic bacteria. *Antimicrob Agents Chemother* 2004;48:2173–2178.
34. de Oliveira RR, Schwartz-Filho HO, Novaes AB, Taba M. Antimicrobial photodynamic therapy in the non-surgical treatment of aggressive periodontitis: a preliminary randomized controlled clinical study. *J Periodontol* 2007;78:965–973.
35. Alves E, Faustino MA, Neves MG, Cunha A, Tome J, et al. An insight on bacterial cellular targets of photodynamic inactivation. *Future Med Chem* 2014;6:141–164.
36. Kranz S, Guellmar A, Volpel A, Gitter B, Albrecht V, et al. Photodynamic suppression of *Enterococcus faecalis* using the photosensitizer mTHPC. *Lasers Surg Med* 2011;43:241–248.

### Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as 'excellent' or 'very good'.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at [microbiologyresearch.org](http://microbiologyresearch.org).